Abemaciclib in Newly Diagnosed Meningioma Patients

A Phase 2 multicenter, double-blind, randomized-controlled study of abemaciclib (CDK4 and 6 Inhibitor) in newly diagnosed RB-proficient grade 3 meningioma participants.